Showing posts with label johns hopkins. Show all posts
Showing posts with label johns hopkins. Show all posts

Tuesday, May 5, 2009

Folic Acid May Help Treat Allergies, Asthma

Folic acid, or vitamin B9, essential for red blood cell health and long known to reduce the risk of spinal birth defects, may also suppress allergic reactions and lessen the severity of allergy and asthma symptoms, according to new research from the Johns Hopkins Children's Center.

In what is believed to be the first study in humans examining the link between blood levels of folate -- the naturally occurring form of folic acid -- and allergies, the scientists say results add to mounting evidence that folate can help regulate inflammation. Recent studies, including research from Johns Hopkins, have found a link between folate levels and inflammation-mediated diseases, including heart disease. A report on the Johns Hopkins Children's findings appears online ahead of print in the Journal of Allergy & Clinical Immunology.

Cautioning that it's far too soon to recommend folic acid supplements to prevent or treat people with asthma and allergies, the researchers emphasize that more research needs to be done to confirm their results, and to establish safe doses and risks.

Reviewing the medical records of more than 8,000 people ages 2 to 85 the investigators tracked the effect of folate levels on respiratory and allergic symptoms and on levels of IgE antibodies, immune system markers that rise in response to an allergen. People with higher blood levels of folate had fewer IgE antibodies, fewer reported allergies, less wheezing and lower likelihood of asthma, researchers report.

"Our findings are a clear indication that folic acid may indeed help regulate immune response to allergens, and may reduce allergy and asthma symptoms," says lead investigator Elizabeth Matsui, M.D., M.H.S., pediatric allergist at Johns Hopkins Children's. "But we still need to figure out the exact mechanism behind it, and to do so we need studies that follow people receiving treatment with folic acid, before we even consider supplementation with folic acid to treat or prevent allergies and asthma."

The current recommendation for daily dietary intake of folic acid is 400 micrograms for healthy men and non-pregnant women. Many cereals and grain products are already fortified with folate, and folate is found naturally in green, leafy vegetables, beans and nuts.

Other findings of the study:

People with the lowest folate levels (below 8 nanograms per milliliter) had 40 percent higher risk of wheezing than people with the highest folate levels (above 18 ng/ml).
People with the lowest folate levels had a 30 percent higher risk than those with the highest folate levels of having elevated IgE antibodies, markers of allergy predisposition.
Those with the lowest folate levels had 31 percent higher risk of atopy (allergic symptoms) than people with the highest folate levels.
Those with lowest folate levels had 16 percent higher risk of having asthma than people with the highest folate levels.
Blacks and Hispanics had lower blood folate levels - 12 and 12.5 nanograms per milliliter, respectively - than whites (15 ng/ml), but the differences were not due to income and socio-economic status.

The Johns Hopkins team is planning a study comparing the effects of folic acid and placebo in people with allergies and asthma.

Asthma affects more than 7 percent of adults and children in the United States, and is the most common chronic condition among children, according to the Centers for Disease Control and Prevention. Environmental allergies are estimated to affect 25 million Americans, according to the CDC.

Co-investigator on the study: William Matsui, M.D, of the Johns Hopkins Kimmel Cancer Center.

The research was funded by the National Institutes of Health.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Friday, February 20, 2009

Clot-Buster Boosts Survival, Decreases Disability for Deadly Subset of Stroke

New results from a multicenter study led by Johns Hopkins show that patients who got an experimental clot-busting treatment for a particularly lethal form of stroke were not only dramatically more likely to survive but also continued to shed lingering disabilities six months later. The findings, announced at the International Stroke Conference in San Diego on Feb. 19, are likely to build support for the use of tissue plasminogen activator (tPA) in patients with intracranial hemorrhage, a treatment-resistant form of stroke marked by brain bleeding.

Last May, study leader Daniel Hanley, M.D., professor of neurology at the Johns Hopkins School of Medicine, and his colleagues reported early findings among 52 intracranial hemorrhage (ICH) patients treated with tPA given by catheter directly into patients' brains to bathe and destroy blood clots with this clot-busting agent. The researchers worked with patients at 38 study sites scattered throughout the United States, as well as in Canada, Germany and Finland.

The treatment, developed by Hanley's team, gives low doses of tPA over several days after strokes involving intracranial hemorrhage.

This drug normally isn't recommended for conditions that involve bleeding, such as ICH, because it can increase the risk of further hemorrhage. However, since tPA is effective at breaking up clots in other conditions, such as heart attacks and other types of strokes, Hanley and his colleagues have been studying its safety and efficacy for treating ICH.

Early results from this study using information collected 30 days after tPA treatment showed that about 80 percent survived, compared to data from previous studies showing that about 80 percent of untreated ICH patients die. In the new study, the researchers report on the patients' progress six months after treatment using assessments for overall levels of disability as well as their skill in accomplishing specific tasks often affected by stroke, such as dressing, bathing or walking.

The researchers found that about 10 percent of patients had no lingering disability after six months. Another 40 percent had only mild to moderate disability and were independently caring for themselves at home by 180 days, but required assistance with everyday tasks such as lifting heavy objects. Even patients who were initially more severely disabled continued to improve months after treatment, with the majority scoring lower on disability assessments after six months compared to the same assessments taken at 30 days.

"We're painting a pretty good picture for quality of life after our treatment for ICH," Hanley says. "Survival doesn't have to mean just getting by-we're showing that it can mean truly living again."

Hanley adds that patients, families, physicians and ethicists worry deeply about the impact of stroke treatments that keep patients alive but leave them with a sharply curbed quality of life. "Our new treatment appears to greatly increase patients' chances for survival and quality of life similar to what they experienced before they had their stroke," he says.

Intracerebral hemorrhage, or ICH, causes blood to pool and clot inside the brain's interior cavities, building up pressure within the brain. The higher pressure, along with inflammation caused by chemicals in the trapped blood, can irreversibly damage the brain, usually leading to death or extreme disability.

Hanley and colleagues, with a clinical planning grant from the National Institute of Neurological Diseases and Stroke will design a pivotal test to assess the value of tPA therapy on a much larger group of ICH patients. They expect to start this clinical trial imminently..

Other Johns Hopkins researchers who participated in this study include Wendy Ziai, M.D.; Ricardo Carhuapoma, M.D.; Neal Naff, M.D.; Becky Sullivan, M.B.A.; Timothy Morgan, B.S.; Eric Melnychuk, B.A., E.M.T.-B; Susan Rice, R.N., M.P.H., C.C.R.P.; Amber Stahl, B.A.; Shannon LeDroux, B.S.; Amanda Bistran, B.S.; and Karen Lane, C.M.A., C.C.R.P.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Wednesday, February 18, 2009

Johns Hopkins Leads First 12-Patient, Multicenter "Domino Donor" Kidney Transplant

Surgical teams at The Johns Hopkins Hospital, Barnes-Jewish Hospital in St. Louis and Integris Baptist Medical Center in Oklahoma City successfully completed Saturday the first six-way, multihospital, domino kidney transplant. All six donors — one man and five women, and six organ recipients – four men and two woman — are in good condition, according to Robert Montgomery, M.D., Ph.D., chief transplant surgeon at Johns Hopkins.

The procedure, kidney paired donation (KPD), takes a group of incompatible donor-recipient pairs (recipients coming to one of the three hospitals with a willing donor who is not compatible by blood or tissue) and matches them with other pairs in a similar predicament. By exchanging kidneys between the pairs, it is possible to give each recipient a compatible kidney. In this way each recipient receives a kidney from a stranger and transplants are enabled that otherwise would not have taken place. Involving multiple hospitals created even more possibilities for matches.

In Saturday’s so-called domino swap, a surgical team made up of nine surgeons, six anesthesiologists and 12 nurses began a cross-country set of operations with five incompatible pairs. An altruistic donor and a recipient who was next on the United Network for Organ Sharing (UNOS) organ recipient list started and ended the domino. Altruistic donors are those willing to donate a kidney to any needy recipient.

Just like falling dominoes, the altruistic donor kidney went to a recipient from one of the incompatible pairs, that recipient’s donor’s kidney went to a recipient from a second pair and so on. The last remaining kidney from the final incompatible pair went to the UNOS recipient.

As part of this complex procedure, Johns Hopkins flew one kidney to Integris Baptist; Integris Baptist flew one kidney to Barnes-Jewish and Barnes-Jewish flew one kidney to Johns Hopkins.

“We have performed a six-way domino procedure at our hospital before,” says Montgomery. “But this is the first time we have done something this ambitious on such a grand scale involving two other hospitals. This will serve as a blueprint for national match in which kidneys will be transported around the country resulting in an estimated 1,500 additional transplants each year.”

The 12 surgeries — all of which must start at the same time — began at 7 a.m. Eastern time. The nine surgeons in charge included four at Johns Hopkins, three at Integris Baptist and two at Barnes-Jewish. All finished by 7 p.m. Eastern time.

Johns Hopkins surgeons performed one of the first KPD transplants in the United States in 2001, the first triple-swap in 2003, the first double and triple domino transplant in 2005, the first five-way domino transplant in 2006 and the first six-way domino transplant in 2007. Johns Hopkins also performed the first multihospital, transcontinental three-way swap transplant in 2007.

Nearly 100 medical professionals took part in the transplants, including immunogeneticists, anesthesiologists, operating room nurses, nephrologists, transfusion medicine physicians, critical care doctors, nurse coordinators, technicians, social workers, psychologists, pharmacists, financial coordinators and administrative support people.

The other surgeons who participated in the surgery were Mohamad Allaf, M.D., Andrew Singer, M.D., and Dorry Segev, M.D., from Johns Hopkins Department of Surgery; Scott Samara, M.D., Shea Samara, M.D., and William Miller, M.D., from Integris Baptist Medical Center; and Surendra Shenoy, M.D., Ph.D.. and Martin Jendrisak, M.D., from Barnes-Jewish Hospital.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Friday, February 6, 2009

A Better Mesh: Researchers 'Tighten' Body's Protective Coating

A net with large holes won't catch small fish. Likewise, the microscopic fibers in the protective mucus coatings of the eyes, lungs, stomach or reproductive system naturally bundle together and allow the tiniest disease-causing bugs, allergens or pollutants to slip by. But Johns Hopkins researchers have discovered a way to chemically shrink the holes in the mucus layer's netting so that it will keep out more of the unwanted particles.

"The mucus layer is an outstanding barrier to most things, but not a perfect one for objects smaller than several hundred nanometers [about 1,000 times smaller than the width a human hair]. We still get sick far too often," says Samuel Lai, a chemical and biomolecular researcher in the Whiting School of Engineering and a member of the university's Institute for NanoBioTechnology (INBT).

"The question we asked was, Can we shrink the size of the holes in the human mucus barrier to help prevent its penetration by potentially harmful nano-size objects?" says Justin Hanes, principal investigator of the study and a professor of chemical and biomolecular engineering. Hanes also is director of therapeutics for the INBT.

The team showed that tiny strands in the mucus layer — the mucin fibers — naturally tend to bundle and bunch together, creating gaps large enough for pathogens and potentially dangerous pollutants to get in. But by adding a simple detergent to the mix, Lai and his colleagues partially disrupted the bundling of mucin fibers, a procedure that decreased the size of the holes in the mesh. Particles in the range of 200 nanometers in diameter that previously slipped through easily now became trapped in the more finely strung netting.

The findings were reported in the January 28 online edition of the journal Public Library of Science One. For this research, the team studied protective coatings taken from the female reproductive tract, conducting high- resolution microscopy experiments with particles as large as 1 micron and as small as 100 nanometers in size.

To shrink the holes in the network's mesh, the researchers used a detergent commonly found in many personal care products. Mucus treated with the detergent slowed nanoparticle movement dramatically, especially in the 200- 500 nanometer range, which was clearly demonstrated in videos enhanced by fluorescent imaging.

"We suspected the fibers are bundled together, making large holes in the mucus mesh, but this was the first time it was shown definitively," says Ying-Ying Wang, a doctoral student and National Science Foundation graduate fellowship recipient in biomedical engineering. "And we didn't know going into this study exactly how much we could shrink the holes, if at all. It was exciting to see particles the size of many potentially dangerous substances become completely trapped in mucus, since mucus-trapping typically leads to harmless removal from our bodies," Wang adds.

The team, which also includes Richard Cone, a biophysics professor and INBT-affiliated faculty member from the Krieger School of Arts and Sciences, and Denis Wirtz, professor of chemical and biomolecular engineering and INBT's associate director, envisions many potential applications for this concept.

"If there is an outbreak of influenza, for example, we imagine that doctors and nurses could inhale these agents in an aerosolized form and be protected against the virus for several hours," Lai says. "People who work where there are high levels of nanoparticles in the air, such as mine workers or builders, could use a product with these fiber debundling detergents to prevent dangerous exposure."

Since the mucus layer constantly clears from the body, any enhancement to its protective ability would be short-lived, adds Lai. For example, coatings clear from the lungs in as little as 30 minutes, while the mucus lining in the stomach and intestine takes several hours to renew. This study is only a start, Lai explains, and the technique has not yet been tested in humans. "The next step will be to try different substances, perhaps those paired to specific pathogens, and observe how these substances improve the performance of the mucus barrier," he says. In addition, microbe-killing agents could be combined with detergents to not only slow but destroy the trapped potential pathogens, he says. Animal studies are being planned.

This work was funded by the National Institutes of Health and a graduate research fellowship from the National Science Foundation.

The study — Samuel K. Lai, Ying-Ying Wang, Richard Cone, Denis Wirtz and Justin Hanes; Altering Mucus Rheology to "Solidify" Human Mucus at the Nanoscale — can be viewed online at: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone. 0004294.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Monday, February 2, 2009

Hopkins Transplant Surgeons Remove Healthy Kidney Through Donor's Vagina

In what is believed to be a first-ever procedure, surgeons at Johns Hopkins have successfully removed a healthy donor kidney through a small incision in the back of the donor’s vagina.

“The kidney was successfully removed and transplanted into the donor’s niece, and both patients are doing fine,” says Robert Montgomery, M.D., Ph.D., chief of the transplant division at Johns Hopkins University School of Medicine who led the team that performed the historic operation.

The transvaginal donor kidney extraction, performed Jan. 29 on a 48-year-old woman from Lexington Park, Md., eliminated the need for a 5-to-6-inch abdominal incision and left only three pea-size scars on her abdomen, one of which is hidden in her navel.

Transvaginal kidney removals have been done previously to remove cancerous or nonfunctioning kidneys that endanger a patient’s health, but not for healthy kidney donation. Because transplant donor nephrectomies are the most common kidney removal surgery — 6,000 a year just in the United States — this approach could have a tremendous impact on people’s willingness to donate by offering more surgical options,” says Montgomery.

“Since the first laparoscopic donor nephrectomy was performed at Johns Hopkins in 1995, surgeons have been troubled by the need to make a relatively large incision in the patient’s abdomen after completing the nephrectomy to extract the donor kidney. “That incision is thought to significantly add to the patient’s pain, hospitalization and convalescence,” says Montgomery. “Removing the kidney through a natural opening should hasten the patient’s recovery and provide a better cosmetic result.”

Both laparoscopies and transvaginal operations are enabled by wandlike cameras and tools inserted through small incisions. In the transvaginal nephrectomy, two wandlike tools pass through small incisions in the abdomen and a third flexible tool housing a camera is placed in the navel.

Video images displayed on monitors guide surgeons’ movements. Once the kidney is cut from its attachments to the abdominal wall and arteries and veins are stapled shut, surgeons place the kidney in a plastic bag inserted through an incision in the vaginal wall and pull it out through the vaginal opening with a string attached to the bag.

Montgomery says the surgery took about three and a half hours, roughly the same as a traditional laparoscopic procedure.

The Jan. 29 operation is one of a family of new surgical procedures called natural orifice translumenal endoscopic surgeries (NOTES) that use a natural body opening to remove organs and tissue, according to Anthony Kalloo, M.D., the director of the Division of Gastroenterology at Johns Hopkins University School of Medicine and the pioneer of NOTES. The most common openings used are the mouth, anus and vagina.

Since 2004, successful NOTES in humans have removed diseased gallbladders and appendixes through the mouth, and gallbladders, kidneys and appendixes through the vagina.

Recently, Kalloo says, some medical experts have called for more studies to compare the safety and effectiveness of NOTES against traditional laparoscopies, which also leave very small scars, have been in use for many years, and are proven to be safer and less painful for patients than older “open” abdominal procedures. He supports more studies.

But, he adds, “natural orifice translumenal endoscopic surgery is the final frontier to explore in making surgery scarless, less painful and for obese patients, much safer.” An organ donor, in particular, is most deserving of a scar-free, minimally invasive and pain-free procedure.”

Additional surgeons from Johns Hopkins University School of Medicine who participated in the procedure were Mohamad E. Allaf, M.D., assistant professor in the departments of Urology and Biomedical Engineering and director of minimally invasive and robotic surgery; Andy Singer, M.D., Ph.D., assistant professor in the Division of Transplant Surgery; and Wen Shen, M.D., M.P.H., assistant professor in the Department of Gynecology and Obstetrics.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, January 22, 2009

Surviving Dance Club Music (Noise) with Hearing Intact

By tweaking a system in the ear that limits how much sound is heard, a global team of researchers has discovered one alteration that shows that the ability of the ear to turn itself down contributes to protecting against permanent hearing loss. The report appears this week in PLoS Biology.

“There’s some uncertainty in the field about what this sound-limiting system is used for,” says Paul Fuchs, Ph.D., an author on the paper and professor of otolaryngology-head and neck surgery and co-director of the Center for Sensory Biology at the Institute for Basic Biomedical Sciences at Johns Hopkins. “Now we’ve definitively shown that this system functions in part to prevent acoustic trauma.”

To get a better handle on this sound-limiting system in the ear, the research team built on previous findings in the field and focused their efforts on the nAChR protein found on so-called sensory hair cells in the ear. Nerve cells from the brain release signals that are picked up by nAChR and turn down these sensory hair cells.

The team genetically altered a single building block in the nAChR protein and tested mice for their ability to hear. “This point mutation was designed to produce a so-called gain of function in which the inhibitory effect of ACh should be greater than normal,” says Fuchs.

The altered mice were less able to hear soft sounds than normal mice, showing that the genetic alteration made in the nAChR protein did indeed further “turn down” the ear. The team then asked if the alteration in nAChR, and therefore the improved sound-blocking ability of these altered mice, also could protect from sound damage.

The team blasted 100-decibel sound at mice and again measured their ability to hear. “One hundred decibels, for me, is painfully loud, and conversation is impossible,” says Fuchs. “But sound levels in night clubs or rock concerts can be that high, and extended exposure to sound at that volume can cause hearing loss.”

They found that mice with the altered, gain-of-function nAChR suffered less permanent hearing damage compared to normal mice. “We think this pathway could be a therapeutic target for protecting from sound damage,” says Fuchs. “So far, there is little or no specific pharmacology of hearing. We’re still learning how the inner ear works. The encouraging news is that molecular mechanisms like the hair cell’s nAChR frequently involve unique gene products, so there is a real chance of finding ear-specific drugs in the future.”

Until then, Fuchs suggests limiting time spent at rock concerts, and wearing earplugs, to protect your hearing.

This study was funded by the National Institutes of Deafness and other Communication Disorders, the Howard Hughes Medical Institute, the National Organization for Hearing Research, the Tinnitus Research Initiative, the Agencia Nacional de Promoción Científica y Tecnológica of Argentina, and the University of Buenos Aires.

Authors on the paper are Paul Fuchs of Johns Hopkins; Julian Taranda, Jimena Ballestero, Eleonora Katz, Jessica Savino and A. Belen Elgoyhen of Instituto de Investigaciones en Ingenieria Genetica y Biologia Molecular in Buenos Aires, Argentina; Stephane Maison and M. Charles Liberman of Harvard Medical School; Douglas Vetter of Tufts University School of Medicine; and Jim Boulter of University of California, Los Angeles.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Wednesday, January 21, 2009

Kidney Transplant Survival can be Long-Term for People with HIV

A Johns Hopkins study finds that HIV-positive kidney transplant recipients could have the same one-year survival rates for themselves and their donor organs as those without HIV, provided certain risk factors for transplant failure are recognized and tightly managed.

“Kidney transplantation is a viable and necessary option for HIV-positive patients with chronic kidney disease, especially since kidney disease is taking such a large toll on this group,” says Jayme Locke, M.D., a resident in the Department of Surgery at Johns Hopkins University School of Medicine, and lead researcher of the study described in the January issue of the Archives of Surgery.

Traditionally, HIV patients were not considered transplant candidates because survival rates after transplantation were thought to be greatly compromised by the disease, which cripples the body’s immune system. Transplant patients also take drugs that suppress their immune systems in order to prevent organ rejection, a regimen thought to further threaten their already fragile immune systems.

Locke says their study results are in part a reflection of newer antiretroviral therapies that have reduced HIV death rates by 80 percent. Indeed, people with HIV now die like most other people, of chronic diseases, rather than from the opportunistic infections that once took a grave toll. Kidney disease, for example, accounts for more than 10 percent of HIV-related deaths.

For the study, Locke and her team looked at the one-year kidney survival rates and one-year patient survival rates of 36,492 HIV-negative and 100 HIV-positive kidney transplant recipients listed on the United Organ Sharing Network (UNOS) list who received transplants between January 2004 and June 2006. They excluded those under 18 and anyone who had multi-organ transplantation.

The chances of survival were the same in both groups. However, kidney survival rates in these two groups showed that HIV-negative recipients had a 94.6 percent survival rate, compared to 87.9 percent in people with HIV. (People can survive on dialysis even if their transplanted kidney fails.)

However, when the investigators broke down the results into subgroups, they learned that some of the kidneys transplanted into HIV-positive recipients were relatively late getting to full function. This so-called delayed graft function (DGF) reduced kidney survival by 30 percent. When this group was removed from the rate comparison, both HIV-positive and HIV-negative groups had equal kidney and patient survival rates, says Locke.

According to Locke, this is significant because DGF can be avoided by controlling certain negative risk factors such as advanced organ donor age, deceased-donor kidneys (vs. live-donor kidneys) and long cold ischemic times (the time the kidney is without blood flow before transplant).

Other researchers who contributed to this study from Johns Hopkins University School of Medicine include Robert Montgomery, M.D., Ph.D.; Daniel S. Warren, Ph.D.; and Dorry Segev, M.D., of the Department of Surgery; and Aruna Subramanian, M.D., of the Department of Medicine.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Wednesday, January 14, 2009

Completely Predictable: Cholera in Zimbabwe

Zimbabwe’s cholera crisis, which has caused more than 1,900 deaths, is a “manmade disaster” caused by President Robert Mugabe’s government, according to a January 13 report by Physicians for Human Rights (PHR), co-authored by Johns Hopkins Bloomberg School of Public Health researcher Chris Beyrer, MD, MPH ’90.

The report, which presents qualitative data derived from interviews with health care workers, engineers, school teachers, NGO and UN representatives, and other officials in the country, attributes the epidemic to Mugabe’s intentional neglect of water treatment and sanitation services, which have fallen into severe disrepair since he was accused of electoral fraud and political violence during run-off elections this summer.

Beyrer, director of the Johns Hopkins Center for Public Health and Human Rights, gathered data in Zimbabwe with three other PHR physicians during a covert five-day visit to the country in mid-December. Escorted by a group of Zimbabwean doctors, Beyrer and colleagues, in-country on tourist visas, toured four provinces, in both rural and urban locations. The general hospitals were “bolted closed,” said Beyrer, the cholera hospitals were under tight surveillance, and the mission hospitals were stretched beyond the point of being able to deliver medical supplies or even running water.

“Zimbabwe offers a classic lesson in public health,” said Beyrer. “When government neglects its basic functions, citizens die. The cholera epidemic in Zimbabwe is completely predictable and preventable. It’s the outcome of the collapse of the most basic water and sanitation measures.”

The health care infrastructure in Zimbabwe has been deteriorating since 2000, when Mugabe began a “land reform” program that undermined the nation’s agriculture industry and crippled the economy. After the disputed polls this summer and a UN order to share power with his political rival in September, Mugabe became proactive in his punishment of Zimbabweans. According to Beyrer, professor of Epidemiology, Mugabe created an extreme breakdown of the health care system.

“You can’t mistake the stench of the sewage,” said Beyrer. In all provinces visited, he and his colleagues observed ruptured sewage pipes and garbage that lines the dirt roads alongside ditches. “There’s open sewage,” said Beyrer. “In some towns, citizens have built walls of garbage—the garbage hasn’t been collected in months.”

The outlook for cholera in the country is grim. The monsoon rains are just beginning in Zimbabwe now, after five months of a cholera crisis, and Beyrer expects the epidemic to worsen.

As a stopgap measure, said Beyrer, aid groups can provide medicine and food. But the crisis may intensify to a degree that the international community would intervene in Zimbabwe against Mugabe’s wishes, acting on a controversial concept known as Responsibility to Protect (a UN-endorsed concept that obligates the international community to respect, protect and fulfill nations’ rights to sovereignty).

A telling footnote to the cholera story, said Beyrer, is the prevalence they observed, among Zimbabweans, of pellagra, a vitamin deficiency disease precipitated by a carbohydrates-only diet. Health officials in Zimbabwe are not allowed to report malnutrition, because no one is supposed to be starving in Zimbabwe, the nation formerly known as “the breadbasket of the world.”

“All of this is evidence of why good government is so central to public health,” said Beyrer. “The basic functions of public health really are state functions. When a state ceases in that, public health fails.” — Christine Grillo

Read In Zimbabwe, a Cancer Called Mugabe, by Chris Beyrer and Frank Donaghue, in the Washington Post.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, November 13, 2008

Heart Association Call for Routine Screening of Heart Patients for Depresssion is Premature, Johns Hopkins Expert Says

A Johns Hopkins cardiologist well known for his studies on the links between depression and heart attack says there is not nearly enough evidence yet to support a recent call by the American Heart Association (AHA) to begin routine screening of millions of Americans for depression.

Roy Ziegelstein, M.D., says the September 2008 recommendation is "premature," and "a massive undertaking" that would consume a vast amount of clinic staff time and effort to analyze and follow-up on the questionnaires involved in screening, without a demonstrated benefit in improving patient care.

An estimated 80 million Americans have some form of heart disease.

Reporting on a collection of more than 1,500 clinical studies from around the world, from which 17 were selected for detailed review, Ziegelstein and his colleagues point to the absence of any scientific proof that depressed heart patients live longer or fare better over the long term if they are screened for depression and treated with drugs and other therapy.

The team's report, believed to be the largest, most comprehensive review of all research in the field, is set to appear in the Nov. 12 edition of the Journal of the American Medical Association. Its publication is timed to coincide with the AHA's annual Scientific Sessions in New Orleans.

"Our analysis showed that depression screening tools worked reasonably well in identifying who is depressed and who is not, based on such symptoms as feeling blue or suddenly withdrawing from routine activities," says Ziegelstein, a professor at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute.

Yet he points out that that about one in five people with depression would not be picked up by screening and fewer than half of those identified as depressed by the screening process will actually be depressed when evaluated more thoroughly.

The team also found that treating depression in people with heart disease only accounted for a 1 percent to 4 percent change in symptoms compared to those treated with placebo. Ziegelstein says this is "too low to expect meaningful benefits for many people, particularly since screening methods are not very precise in identifying people who would benefit from the treatment."

In addition, he says, before routine screening, physicians need to consider the potential for harm to people, as no studies have fully analyzed any negative impact from treatment side effects, or misdiagnosis and labeling of heart patients as depressed.

"Understandably, then, we cannot in good conscience support screening all heart patients," says Ziegelstein, vice chairman of medicine at Johns Hopkins Bayview Medical Center.

"This is a difficult call for us to make, but it is in the best interests of patients at this time," he adds.

The AHA estimates that one in four heart attack patients experiences feelings of sadness and develops a gloomy outlook as a result of the injury. Such depression more than doubles the risk of death, according to some studies.

But rather than massive, costly screening at this point, Ziegelstein says physicians need to "get to know their patients better, as real people," and to make clinical assessments of each patient's mood for signs of depression as they talk to them about other things related to their health, including exercise routines, dietary habits, and use of medications.

"Physicians can start by listening more to their patients during examinations and by not interrupting them, which research shows often happens within the first 20 seconds after patients initiate conversation," he says.

Making a diagnosis of depression is not difficult, he adds, "if they use their examination time well and ask the right questions," not focusing only on the physical issues but also on the patient's overall state of well-being and daily routine.

"Look and listen for signs of low mood or sadness, or find out if a patient has recently stopped or cut back on social contacts or things they used to do for fun," says Ziegelstein.

As part of the research review, an international team of researchers sorted over 1,500 clinical studies of depression to identify studies that looked at screening heart patients for depression, treating and monitoring them. From these, the team, led by Johns Hopkins-trained psychologist Brett Thombs, Ph.D., now an assistant professor at McGill University in Montreal, grouped together the data from 11 studies that used proven depression screening tests.

Selected screening studies covered more than 4,000 men and women, and most involved one of four commonly used questionnaires to diagnose depression. Results showed that these tests were on average 80 percent accurate in detecting people who were actually depressed.

Another half-dozen clinical trials were evaluated for the immediate health effects of drug treatment and counseling among nearly 3,000 men and women who had been screened and found to be depressed. Drug treatment mostly involved prescribing mood-raising selective serotonin reuptake inhibitors.

Researchers could not find a single study that screened heart patients for depression and then demonstrated lasting improvements to health or even a longer lifespan.

"We don't have any evidence that screening for depression will benefit people with heart disease. What we really need is more research on how best to help them adopt healthy behaviors that combat depression, such as how to stop smoking, exercise regularly and maintain a healthy weight," says Thombs.

Ziegelstein says the team's collective research will contribute to a better understanding of how depression influences heart disease. He also says it will increase physician support to broaden clinical care of depressed heart patients to include increased input from psychologists, psychiatrists and internists, as part of what he calls a more "collaborative care model" that encompasses as much care of the mind and overall body as it does the physical heart.

Funding support for Ziegelstein's research was provided by the National Center for Complementary & Alternative Medicine, a member of the National Institutes of Health, and by the Miller Family Scholar Program.

In addition to Ziegelstein and Thombs, other researchers who contributed to this study were Cheri Smith, M.L.S., and Karl Soderlund, B.S., at Johns Hopkins. International co-investigators were Peter de Jonge, Ph.D., at the University Medical Center Groningen, Netherlands; James Coyne, Ph.D., at the University of Pennsylvania School of Medicine, in Philadelphia; Mary Whooley, M.D., at the University of California, San Francisco; Nancy Frasure-Smith, Ph.D., also at McGill; Alex Mitchell, M.Sc., M.R.C. Psych, at the Leicester Royal Infirmary, United Kingdom; Marij Zuidersma, M.Sc., also at Groningen; Chete Eze-Nliam, M.D., M.P.H., at Interfaith Medical Center in Brooklyn, N.Y.; and Bruno Lima, at Federal University of Ceara School of Medicine, in Fontalez-ce, Brazil.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Wednesday, November 5, 2008

Noted Hopkins Scientist Says Research Indicates Need For Effective HPV Vaccine For Women And Men And A Simple HPV Screening Test

A call to explore a broader use of HPV (human papillomavirus) vaccines and the validation of a simple oral screening test for HPV-caused oral cancers are reported in two studies by a Johns Hopkins Kimmel Cancer Center investigator.

Leading HPV expert Maura Gillison, M.D., Ph.D., the first to identify HPV infection as the cause of certain oral cancers and who identified multiple sex partners as the most important risk factor for these cancers, reports her latest work in the November 3, 2008, journal Clinical Cancer Research and in a Centers for Disease Control and Prevention (CDC) monograph. The CDC report on HPV-associated cancers appears on line November 3 and in the November 15, 2008, supplement edition of Cancer.

In the CDC report, believed to be the first and most comprehensive assessment of HPV-associated cancer data in the United States, investigators analyzed cancer registry data from 1998-2003 and found 25,000 cancer cases each year occurred at cancer sites associated with HPV infection. In additional analysis, Gillison and colleagues at the National Cancer Institute identified HPV infection as the underlying cause of approximately 20,000 of these cancers.

Gillison and team found approximately 20,000 cases of cancer in the United States each year are caused by HPV infection. Oral cancers are the second most common type of HPV-associated cancers and are increasing in incidence in the U.S., particularly among men. Add to that anal, penile, vaginal, and vulvar cancers that are also linked to HPV infection, and Gillison says these cancers, when combined, equal the number of cervical cancers, the most common and well known of the cancers caused by HPV.

While about one-quarter of HPV-linked cancers occur in men, vaccines are currently approved only for use in girls and young women for cervical cancer prevention. “We need to have a more comprehensive discussion of the potential impact the HPV vaccine could have on cancer rates among men and women in this country,” says Gillison, associate professor of oncology. “Currently available HPV vaccines have the potential to reduce the rates of HPV-associated cancers, like oral and anal cancers, that are currently on the rise and for which there no effective or widely-applied screening programs.” Gillison notes, however, that studies are needed to confirm that the vaccine effectively prevents HPV infections that lead to oral and anal cancers.

Gillison’s findings were part of a project known as ABHACUS (Assessing the Burden of Human Papillomavirus-Associated Cancers). The data studied came from the CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. More than 80 investigators from across the country participated in the project, which addressed a variety of HPV-cancer associated issues, including racial disparity, economic impact, behavioral risk factors, and cancer mortality.

Other then prevention, early detection is held by cancer experts as the best way to control cancer. In the Clinical Cancer Research study, the first to track the disease and related oral infections over an extended period, Gillison found that simple “swish and spit” oral rinses can successfully track oral HPV infection over time. These findings open the door to a potential, non-invasive screening test to detect the disease and monitor for tumor recurrence. Head and neck cancer is the broad term for a variety of cancers of the oral cavity, including the tonsils, base of the tongue, and the side and back wall of the throat.

The study found that oral rinses successfully detected high-risk HPV infections in patients with HPV 16-positive head and neck cancers for up to five years after treatment for their cancer. Gillison says the findings indicate a high rate of persistent infection and reaffirms the connection between high-risk types of HPV and HPV-positive head and neck cancers.

In the study, the researchers used oral rinses to collect cells shed from inside the mouths of 135 head and neck cancer patients. The researchers genetically sequenced the DNA obtained from the rinses and tumor samples to identify those with HPV-positive cancers and determine the HPV type. There are approximately 120 types of HPV, but HPV 16 is one of the two most common associated with cancer.

The analysis revealed 44 patients with HPV 16-positive tumors and found that these patients were more likely to have continuing oral HPV 16 infections both before and after cancer treatment. While this study did not link the continued post-treatment infections to tumor recurrence, it was noted that patients with high-risk oral HPV infections prior to therapy, maintained high rates of infection after completing therapy. The team plans further, long-term research to determine if this continued infection leads to cancer recurrence.

In 2000, Gillison identified HPV-positive head and neck cancer as a distinct subtype of the disease and linked it to improved survival.

“There is no question of cause,” says Gillison. “It has now become a question of tracking the infection over time to identify those at risk of developing cancer or cancer recurrence.”

Other researchers participating in the study include Yuri Agrawal, Wayne M. Koch, Weihong Xiao, William H. Westra, Anna L. Trivett, and David E. Symer.

The research was funded by the Oral Cancer Foundation, the National Institute of Dental and Craniofacial Research, and the National Cancer Institute.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Wednesday, October 29, 2008

Drinking Milk to Ease Milk Allergy?

HHH Note: This study is promising. It does, however, come with the warning NOT to try this at home.

Giving children with milk allergies increasingly higher doses of milk over time may ease, and even help them completely overcome, their allergic reactions, according to the results of a study led by the Johns Hopkins Children’s Center and conducted jointly with Duke University.

Despite the small number of patients in the trial – 19 – the findings are illuminating and encouraging, investigators say, because this is the first-ever double-blinded and placebo-controlled study of milk immunotherapy. In the study, the researchers compared a group of children receiving milk powder to a group of children receiving placebo identical in appearance and taste to real milk powder. Neither the patients nor the investigators knew which child received which powder, a rigorous research setup that minimizes the chance for error and bias.

The findings of the study are reported online ahead of print, Oct. 28, in the Journal of Allergy & Clinical Immunology

“Our findings suggest that oral immunotherapy gradually retrains the immune system to completely disregard or to better tolerate the allergens in milk that previously caused allergic reactions,” says Robert Wood, M.D., senior investigator on the study and director of Allergy & Immunology at Hopkins Children’s. “Albeit preliminary and requiring further study, these results suggest that oral immunotherapy may be the closest thing yet to a ‘true’ treatment for food allergy.”

Currently, food allergy management involves complete avoidance of the trigger foods, waiting for the child to outgrow the allergy or treating allergic reactions if and when they occur. The latter could be dangerous, investigators say, because these common foods are difficult to avoid and some reactions can be severe and even life-threatening.

In a report released Oct. 22, the Centers for Disease Control and Prevention estimates that food allergies are on the rise with three million children in the United States now having at least one food allergy, an 18 percent jump from 10 years ago. Milk allergy is the most prevalent type of food allergy.

“Given that the quality of life of a child with a food allergy is comparable to the quality of life of a child with diabetes, we urgently need therapies that go beyond strict food avoidance or waiting for the child to outgrow the allergy,” Wood says.

Researchers followed allergic reactions over four months among 19 children with severe and persistent milk allergy, 6 to 17 years of age. Of the 19 patients, 12 received progressively higher doses of milk protein, and seven received placebo. At the beginning of the study, the children were able to tolerate on average only 40 mg (.04 ounces or a quarter of a teaspoon) of milk.

At the end of the four-month study, both groups were given milk powder as a “challenge” to see what dose would cause reaction after the treatment. The children who had been receiving increasingly higher doses of milk protein over a few months were able to tolerate a median dose of 5, 140 mg (over 5 ounces) of milk without having any allergic reaction or with mild symptoms, such as mouth itching and minor abdominal discomfort. Those who had been getting the placebo remained unable to tolerate doses higher than the 40 mg of milk powder without having an allergic reaction. In the group receiving milk protein, the lowest tolerance dose was 2, 540 mg (2.5 ounces) and the highest was 8,140 mg (8 ounces). Lab tests showed the children who regularly drank or ate milk had more antibodies to milk in their blood, yet were able to better tolerate milk than those who took the placebo. Researchers say, tolerance in children treated with milk continued to build over time, and recommend that these children continue to consume milk daily to maintain their resistance. The researchers caution that it remains unclear whether the children would maintain their tolerance once they stop consuming milk regularly. “It may very well be that this tolerance is lost once the immune system is no longer exposed to the allergen daily,” Wood says.

The Hopkins group is currently studying oral immunotherapy in children with egg allergy to determine whether increasingly higher doses of egg protein can help resolve their allergy, and have recently started another study of milk immunotherapy.

Wood emphasizes the findings require further research and advises parents and caregivers not to try oral immunotherapy without medical supervision.

Other Hopkins investigators in the study: Justin Skripak, M.D., Hannah Rowley, R.D., Nga Brereton, R.D., Susan Oh, R.D., Robert Hamilton, M.D., Elizabeth Matsui, M.D. M.H.S.

Duke University co-investigators: Scott Nash, M.D., and A. Wesley Burks, M.D.

The research was funded by the National Institutes of Health and The Eudowood Foundation.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Tuesday, October 28, 2008

Researchers Discover Hydrogen Sulfide Is a Major Regulator of Blood Pressure

Anyone with a nose knows the rotten-egg odor of hydrogen sulfide, a gas generated by bacteria living in the human colon. Now an international team of scientists has discovered that cells inside the blood vessels of mice — as well as in people, no doubt — naturally make the gassy stuff, and that it controls blood pressure.

Having discovered that hydrogen sulfide, or H2S, is produced in the thin, endothelial lining of blood vessels, the researchers, including scientists from Johns Hopkins, report today in Science that H2S regulates blood pressure by relaxing blood vessels. As the newest member of a family of so-called gasotransmitters, this messenger molecule is akin in function, if not form, to chemical signals like nitric oxide, dopamine and acetylcholine that relay signals between nerve cells and excite or put the brakes on mind-brain activities.

“Now that we know hydrogen sulfide’s role in regulating blood pressure, it may be possible to design drug therapies that enhance its formation as an alternative to the current methods of treatment for hypertension,” says Johns Hopkins neuroscientist Solomon H. Snyder, M.D., a co-author of the paper.

Conducting their investigations using mice missing a gene for an enzyme known as CSE, long suspected as responsible for making H2S, the researchers first measured hydrogen sulfide levels in a variety of tissues in the CSE-deficient mice and compared them to normal mice. They found that the gas was largely depleted in the cardiovascular systems of the altered mice, engineered by Rui Wang, M.D., Ph.D., of Lakehead University in Ontario, and Lingyun Wu, M.D., Ph.D., of the University of Saskatchewan, Canada. By contrast, normal mice had higher levels — clear evidence that hydrogen sulfide is normally made by mammalian tissues using CSE.

Next, the scientists applied tiny cuffs to the tails of the mice and measured their blood pressure, noting spikes of about 20 percent, comparable to serious hypertension in humans.

Finally, the team tested how blood vessels of CSE-deficient mice responded to the chemical neurotransmitter methacholine, known to relax normal blood vessels. The blood vessels of the altered mice relaxed hardly at all, indicating that hydrogen sulfide was largely responsible for relaxation.

Because gasotransmitters are highly conserved in mammals, the findings of the research are believed to have broad applications to human physiology and disease.

“In terms of relaxing blood vessels, it looks like hydrogen sulfide might be as important as nitric oxide,” Snyder says, referring to the first gasotransmitter that two decades ago was discovered to regulate blood pressure.

Just because these two gas molecules perform similar functions, doesn’t mean they’re redundant, says Wang, the paper’s principal author. “Nature has added on layer upon layer of complexity to provide a better and tighter control of body function — in this case, of blood pressure.”

Studying gaseous messengers can be tricky, explains Snyder, an authority on nitric oxide (NO) whose lab in 1990 discovered that the enzyme triggering NO production is activated by a protein mechanism known as calcium-calmodulin.

“When a nerve fires, it releases a bit of neurotransmitter. Then it fires again, very quickly, and releases more of the neurotransmitter, which is always in reserve and at the ready in large storage pools called vesicles. However, gasses can’t be stored; they diffuse. So every time there’s a nerve impulse, an enzyme must be activated to make it,” he says.”

Although CSE, the enzyme that activates hydrogen sulfide, was characterized more than half a century ago, the new work is the first to reveal that it is activated in the same way as the nitric oxide-forming enzyme, thus establishing how hydrogen sulfide regulates blood pressure by relaxing blood vessels.

“It’s difficult to overestimate the biological importance of hydrogen sulfide or its implications in hypertension as well as diabetes and neurodegenerative diseases,” Wang says. “In fact, most human diseases probably have something to do with gasotransmitters.”

The research was supported by grants from the U.S. Public Health Service and the Canadian Institutes of Health Research as well as a Research Scientist Award.

Authors on the paper are Guangdong Yang, Lingyun Wu, Bo Jiang, Wei Yang, Jiansong Qi, Kun Cao, Qinghe Meng, all of the University of Saskatchewan, Canada; Wang of the University of Saskatchewan and Lakehead University, Canada; Shengming Zhang of Lakehead University, Canada; and Asif K. Mustafa, Weitong Mu and Snyder, all of Hopkins.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, October 23, 2008

U.S. Suicide Rate Increases

The rate of suicide in the United States is increased for the first time in a decade, according to a new report from the Johns Hopkins Bloomberg School of Public Health’s Center for Injury Research and Policy. The increase in the overall suicide rate between 1999 and 2005 was due primarily to an increase in suicides among whites aged 40-64, with white middle-aged women experiencing the largest annual increase.

Whereas the overall suicide rate rose 0.7 percent during this time period, the rate among middle-aged white men rose 2.7 percent annually and 3.9 percent among middle-aged women. By contrast, suicide in blacks decreased significantly over the study’s time period, and remained stable among Asian and Native Americans. The results are published online at the website of the American Journal of Preventive Medicine and will be published in the December print edition of the journal.

The researchers also conducted a detailed analysis of suicide methods across specific population groups. While firearms remain the predominant method, the rate of firearm suicides decreased during the study period. Suicide by hanging or suffocation increased markedly with a 6.3 percent annual increase among men, and a 2.3 percent annual increase among women.

Hanging/suffocation accounted for 22 percent of all suicides by 2005, surpassing poisoning at 18 percent.

“The results underscore a change in the epidemiology of suicide, with middle-aged whites emerging as a new high-risk group,” said study co-author Susan P. Baker, MPH, a professor with the Bloomberg School’s Center for Injury Research and Policy. “Historically, suicide prevention programs have focused on groups considered to be at highest risk—teens and young adults of both genders as well as elderly white men. This research tells us we need to refocus our resources to develop prevention programs for men and women in their middle years.”

Baker along with colleagues Guoqing Hu, PhD, Holly Wilcox, PhD, Lawrence Wissow, MD, MPH, analyzed data from the Web-based Injury Statistics Query and Reporting System (WISQARS) mortality reports, which provides data on deaths according to cause and intent of injury by age, race, gender and state. WISQARS mortality data are based on annual data files of the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC).

The reasons for the increase in the suicide rate are not fully understood. “While it would be straightforward to attribute the results to a rise in so-called mid-life crises, recent studies find that middle age is mostly a time of relative security and emotional wellbeing,” said Baker. “Further research is warranted to explore societal changes that may be disproportionably affecting the middle-aged in this country.”

The research was funded by the Center for Injury Research and Policy.

-----
www.georgiafrontpage.com
Georgia Front Page
www.fayettefrontpage.com
Fayette Front Page

Friday, October 10, 2008

Mouse Studies Suggest Daily Dose of Ginkgo may Prevent Brain Cell Damage After a Stroke

Working with genetically engineered mice, researchers at Johns Hopkins have shown that daily doses of a standardized extract from the leaves of the ginkgo tree can prevent or reduce brain damage after an induced stroke.

The scientists, in a report published in Stroke, say their work lends support to other evidence that ginkgo biloba triggers a cascade of events that neutralizes free radicals known to cause cell death.

"It's still a large leap from rodent brains to human brains but these results strongly suggest that further research into the protective effects of ginkgo is warranted," says lead researcher Sylvain Doré, Ph.D., an associate professor in the Department of Anesthesiology and Critical Care Medicine. "If further work confirms what we've seen, we could theoretically recommend a daily regimen of ginkgo to people at high risk of stroke as a preventive measure against brain damage."

In the study, researchers gave ginkgo biloba EGb 761 - a lab-quality form of the extract - to normal mice and HO-1 knockout mice, mice lacking the gene that produces the enzyme heme oxygenase-1(HO-1). HO-1 breaks down heme, a common iron molecule found in blood, into carbon monoxide, iron and biliverdin. HO-1 has been shown to act as an antioxidant and have a protective effect against inflammation in animal models.

Doré and his team gave 100 milligrams per kilogram of EGb 761 extract orally once daily for seven days before inducing stroke in the mice by briefly blocking an artery to one side of the brain.

After stroke induction, the mice were tested for brain function and brain damage. One such test, for example, involves running patterns, another tests reaction to an external stimulus. Similar tests were conducted on mice that did not receive the ginkgo extract.

Neurobehavioral function was evaluated before the study and at 1, 2 and 22 hours after stroke using a four-point scale: (1) no deficit, (2) forelimb weakness, (3) inability to bear weight on the affected side, (4) no spontaneous motor activity.

Results showed that normal mice that were pretreated had 50.9 percent less neurological dysfunction and 48.2 percent smaller areas of brain damage than untreated mice. These positive effects did not exist in the HO-1 knockout mice.

"Our results suggest that some element or elements in ginkgo actually protect brain cells during stroke," says Doré.

Roughly 700,000 people experience a stroke in the United States annually. Of those, 87 percent have an ischemic stroke, which is caused by a blocked artery in the brain. Some brain damage occurs simply from the lack of blood getting to brain cells; however, it is known that an increase in the presence of free radicals at the site of an ischemic stroke - once the clot is cleared and the blood supply returns - is also a major cause of resulting brain cell damage. Free radicals are toxic oxygen molecules that are produced when cells die. According to Doré and his team, ginkgo increases HO-1 levels, and the antioxidant properties of this enzyme eliminate free radicals at the surrounding regions of the stroke site.

The only current treatment for ischemic stroke is to clear the clot with tissue plasminogen activator (tPA) or other means. This, however, offers no real protection against the cell damage that occurs when blood flow is restored.

"Ginkgo has long been touted for its positive effects on the brain and is even prescribed in Europe and Asia for memory loss," says Doré. "Now we have a possible understanding for how ginkgo actually works to protect neurons from damage."

Native to China, the ginkgo tree is grown as an ornamental shade tree in Australia, Southeast Asia, Europe, Japan and North America. It is commercially cultivated in France and the United States. It has a grey bark, reaches a height of 35 meters and a diameter of 3 to 4 meters. It has deciduous, fan-like leaves that are green, grey-yellow, brown or blackish.

Additional researchers include Sofiyan Saleem, Ph.D., and Hean Zhuang, M.D., of the Department of Anesthesiology and Critical Care Medicine, and Shyam Biswal, Ph.D., of the Department of Environmental Health Sciences, all from Johns Hopkins.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, September 25, 2008

Big Waistline in Women Could Lead to Heart Trouble

A heart expert at Johns Hopkins is calling for all women with a waistline measuring more than 35 inches to get an annual check-up and detailed risk assessment for heart problems because excess abdominal fat, even in the mildly obese and overweight, leads more than a third of women to underestimate their lifetime risk of having a heart attack, stroke or chest pain (angina.)

Cardiologist Erin Michos, M.D., M.H.S., who plans to make her pitch Sept. 23 directly to colleagues during a special lecture at The Johns Hopkins Hospital, says the recommendation is based on a national, multicity screening of 8,936 women, ages 35 to 63, for heart disease risk factors. The screening, she says, found a strikingly high number of overweight American women whose stretched girth was tied to a serious underestimation of risk using traditional tools to assess heart health.

In a report published in the August issue of the Journal of Women’s Health, the research team showed that 39 percent of women screened were overweight (having a body mass index between 25 and 30) and 35 percent were obese (having a body mass index over 30, often overweight by more than 30 pounds.) And when waistlines 35 inches and larger were factored into the risk assessment, 55 percent of these women were found to have hearts at increased risk of disease.

“It is time for physicians and patients to pull out their measuring tapes and for overweight women in particular to start shedding some pounds,” says Michos, an assistant professor at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute.

She points out that traditional risk-factor scoring leaves out waist size, taking into account only such other factors as age, blood pressure, blood cholesterol levels, smoking and diabetes. These measures have long been used as part of the Framingham Risk Assessment, which only assesses people’s 10-year risk of heart disease.

But the team’s latest assessments – drawn from a 2006 annual public screening in 14 communities across the United States, in which women were asked to undergo a short physical check-up and fill out a health questionnaire – changed significantly when expanded waistlines were factored into their calculations.

More than half (59 percent) of the 85 percent of women originally thought to be at low risk of heart trouble were now found to have one or two additional risk factors. And 19 percent of those at low risk and nearly half (41 percent) of the women originally ranked at intermediate risk actually had three or more risk factors.

“These women have a high lifetime risk of cardiovascular disease even though their 10-year risk may be predicted as low,” says Michos, who points out that the presence of a single, major risk factor for heart disease by the age of 50 cuts back on women’s median lifespan compared to women with no risk factors.

“Our results really emphasize the growing epidemic of obesity in America and showcase its potential for misreading or masking future harm to women’s heart health,” she says. “Even if they are not experiencing immediate problems, they could soon be in trouble. Overweight people are more likely to develop risk factors that lead to cardiovascular problems, such as high blood pressure, blood sugar imbalances and excess blood lipid levels. And the reverse is also true: Losing weight, especially abdominal fat, is the first step in lowering blood pressure and getting blood cholesterol levels under control.”

Michos notes that other research has shown a loss of just five pounds lowers people’s risk of pre-diabetes by 31 percent. Losing 10 pounds lowers blood pressure by 5 millimeters of mercury.

Michos says she has started her campaign with local physicians because it will take a few years to amass the necessary additional evidence to change national clinical guidelines. Results from the 2007 screenings, coordinated by the Maryland-based Sister to Sister, Everyone Has a Heart Foundation, will not be ready until later this year.

“Physicians and others have unfortunately become too accustomed to seeing heavy- set people, and there is a risk that we overlook or dismiss being overweight and obesity as a potential and future source of heart problems,” says Michos. “Even if the problems are not evident now, it is more important to start screening women at a younger age to forego heart problems later in life.

“Community screening events have confirmed that many women are unaware of their risk factors and the screenings have proven effective at identifying those women at risk and, hopefully, we will be able to expand these programs in the future,” she adds, noting that 48 percent of women with high cholesterol levels were newly diagnosed with the condition, as were 7 percent of women with hypertension. “Awareness is the first step to implementing heart-healthy lifestyle changes to reduce their risk,” says Michos. The next Sister to Sister community screening event will take place in February 2009.

Furthermore, Michos says annual survey results, though specific to women, also bear significance for men, for whom a waistline greater than 40 inches is considered obese.
Researchers say their next steps are to monitor screened women to see how well follow-up treatments worked at not only lowering risk, but also in lowering actual heart problems and whether or not this stretches out lifespan.

Of 150 women who were screened as high risk in 2006, 71 percent followed up with a visit to their physician, 64 percent changed diet, 47 percent lost weight, 61 percent monitored their blood pressure levels, 6 percent stopped smoking, and 23 percent checked their waistline against the 35-inch benchmark.

According to the latest statistics from the American Heart Association, one in three American women has some form of cardiovascular disease. Sixty-nine million women are overweight, including more than 36 million who are obese.

Funding for this study was provided by the Sister to Sister, Everyone Has a Heart Foundation. Besides Michos, other researchers from the Johns Hopkins Ciccarone Preventive Cardiology Center involved in this study and the Sister to Sister annual screenings were Brian Kral, M.D., M.P.H.; Catherine Campbell, M.D.; M. Dominique Ashen, Ph.D., C.R.N.P.; and Roger Blumenthal, M.D. Other researchers included Irene Pollin, Ph.D., M.S.W., and Laurene McKillop, Ph.D., from Sister to Sister; Teresa Shattuck, Ph.D., Michele Debarthe Sadler, Ph.D., and Karen Boyle, Ph.D., from Shattuck & Assoc.; Khurram Nasir, M.D., M.P.H., from Massachusetts General Hospital in Boston; Rita Redberg, M.D., from the University of California San Francisco; and Karlynn Brintzenhofeszoc, Ph.D., M.S.W., from Catholic University of America in Washington, D.C.

-----
www.fayettefrontpage.com
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.georgiafrontpage.com
Georgia Front Page

Saturday, September 6, 2008

Hopkins Experts: Most Vaccine-Allergic Children Can Still Be Safely Vaccinated

With close monitoring and a few standard precautions, nearly all children with known or suspected vaccine allergies can be safely immunized, according to a team of vaccine safety experts led by the Johns Hopkins Children’s Center. Writing in the September issue of Pediatrics, the multicenter research team offers pediatricians a step-by-step tool for quickly identifying children with allergic reactions to vaccines, and a much-needed guide, they say, to safely immunize those who are allergic.

Serious allergic reactions to vaccines are extremely rare — one or two per million vaccinations, according to some estimates — but when they happen, such episodes can be serious, even life-threatening, making it critical for pediatricians to instantly spot true allergic reactions and differentiate them from more benign nonallergic responses, investigators say. It is also crucial that pediatricians design a safe immunization plan for children with confirmed vaccine allergies. Children who have had one allergic reaction are believed to be at a higher risk for future reactions, typically more serious than the first.

“We cannot reiterate enough that the vaccines used today are extremely safe, but in a handful of children certain vaccine ingredients can trigger serious allergic reactions,” says Robert Wood, M.D., lead author on the paper and chief of pediatric Allergy and Immunology at Hopkins Children’s. “For the most part, even children with known allergies can be safely vaccinated.”

Given recent outbreaks of vaccine-preventable infections like measles, mumps and whooping cough in the United States, and measles and polio overseas, it is essential to safely vaccinate as many children as possible, investigators say.

Combing through available evidence on vaccine safety and allergies, the Hopkins-led team developed a sequence of instructions – an algorithm – that prompts physicians one step at a time on how to evaluate and immunize children with known or suspected vaccine allergies.

The guidelines are intended for doctors and parents who are uncertain about vaccine safety in children who have already had or are at high risk for having allergic reactions to vaccines.

In such cases, the Hopkins-led group advises a workup by an allergist, including skin prick testing—a prick on the skin or an injection under the skin with a small dose of vaccine or the suspected allergen from the vaccine—or blood tests that would detect the presence of characteristic antibodies that patients develop to allergens, such as antibodies to gelatin or egg proteins used in several common vaccines.

In many cases, allergic children can be vaccinated using alternative forms of a vaccine that are free of the allergen. Even if allergen-free formulations are unavailable, many children can still be vaccinated and remain under physician supervision for several hours after vaccination. Another option is testing the child to check for immunity. If blood tests show the child has already developed protective antibodies, it may be OK, at least temporarily, to withhold further doses of the vaccine, researchers write.

“Vaccines save lives, and parents should know that children who have had allergic reactions after a vaccine are likely to have developed protection against infection as a result of the vaccination,” says investigator Neal Halsey, M.D., an infectious disease specialist at Hopkins Children’s, and professor of International Health at the Johns Hopkins University Bloomberg School of Public Health.

“Most children who have had an allergic reaction after a vaccine can still be vaccinated against other diseases safely and some can receive additional doses of vaccines they might have reacted to,” Halsey adds.

Many children with known vaccine allergies who have low levels of protective antibodies and require more doses can be vaccinated safely under the guidelines. In some cases, children with known allergies can be given antiallergy medications, such as antihistamines and corticosteroids, before vaccination to help ward off or lessen the allergic reaction. For a step-by-step guide to vaccine administration in children with known or suspected vaccine allergy, see the full text of the article at http://pediatrics.aappublications.org/future/122.3.shtml.

Immunizations of children with known vaccine allergies should always be administered under medical supervision in a clinic equipped to treat life-threatening allergic reactions or in a hospital intensive-care unit. Patients can usually go home after an hour or two if they have no adverse reactions.

True allergies typically cause immediate reactions, involving the immune system as a whole that occur within a few minutes to a few hours of vaccination. By contrast, delayed reactions, which occur within days, even weeks after vaccination, are generally benign and are rarely, if ever, dangerous.

Symptoms of immediate allergic reactions include hives, swelling, wheezing, coughing, low blood pressure, vomiting, diarrhea, and can lead to full-blown anaphylaxis, a life-threatening allergic reaction.

The research was funded by the Centers for Disease Control and Prevention.

Co-investigators on the research: Melvin Berger, M.D. Ph.D., University Hospitals of Cleveland; Stephen Dreskin, M.D. Ph.D., University of Colorado; Rosanna Setse, M.D. M.P.H., Johns Hopkins University Bloomberg School of Public Health; Renata Engler, M.D., Walter Reed Army Medical Institute; Cornelia Dekker, M.D., Stanford University School of Medicine. The Clinical Immunization Safety Assessment Network, consisting of six medical research centers with expertise in immunization safety, was part of the study.

Conflict of interest disclosure for Hopkins investigators: Halsey has received research support from vaccine manufacturer Wyeth and is a consultant for vaccine manufacturers GlaxoSmithKline and Merck.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Tuesday, August 12, 2008

Low Vitamin D Levels Pose Large Threat to Health

Researchers at Johns Hopkins are reporting what is believed to be the most conclusive evidence to date that inadequate levels of vitamin D, obtained from milk, fortified cereals and exposure to sunlight, lead to substantially increased risk of death.

In a study set to appear in the Archives of Internal Medicine online Aug. 11, the Johns Hopkins team analyzed a diverse sample of 13,000 initially healthy men and women participating in an ongoing national health survey and compared the risk of death between those with the lowest blood levels of vitamin D to those with higher amounts. An unhealthy deficiency, experts say, is considered blood levels of 17.8 nanograms per milliliter or lower.

Of the 1,800 study participants known to have died by Dec. 31, 2000, nearly 700 died from some form of heart disease, with 400 of these being deficient in vitamin D. This translates overall to an estimated 26 percent increased risk of any death, though the number of deaths from heart disease alone was not large enough to meet scientific criteria to resolve that it was due to low vitamin D levels.

Yet, researchers say it does highlight a trend, with other studies linking shortages of vitamin D to increased rates of breast cancer and depression in the elderly. And earlier published findings by the team, from the same national study, have established a possible tie-in, showing an 80 percent increased risk of peripheral artery disease from vitamin D deficits.

Researchers note that other studies in the last year or so in animals and humans have identified a connection between low levels of vitamin D and heart disease. But these studies, they say, were weakened by small sample numbers, lack of diversity in the population studied and other factors that limited scientists’ ability to generalize the findings to the public at large.

“Our results make it much more clear that all men and women concerned about their overall health should more closely monitor their blood levels of vitamin D, and make sure they have enough,” says study co-lead investigator Erin Michos, M.D., M.H.S.

“We think we have additional evidence to consider adding vitamin D deficiency as a distinct and separate risk factor for death from cardiovascular disease, putting it alongside much better known and understood risk factors, such as age, gender, family history, smoking, high blood cholesterol levels, high blood pressure, lack of exercise, obesity and diabetes,” says Michos. Vitamin D is well known to play an essential role in cell growth, in boosting the body’s immune system and in strengthening bones.

“Now that we know vitamin D deficiency is a risk factor, we can better assess how aggressively to treat people at risk of heart disease or those who are already ill and undergoing treatment,” says Michos, who adds that test screening for nutrient levels is relatively simple. It can, she says, be made part of routine blood work and done while monitoring other known risk factors, including blood pressure, glucose and lipid levels.

Heart disease remains the nation’s leading cause of death, killing more than a million Americans each year. Nearly 10 percent of those with the condition have not one identifiable, traditional risk factor, which the experts say is why a considerable extent of the disease goes unexplained.

Michos, an assistant professor at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute, recommends that people boost their vitamin D levels by eating diets rich in such fish as sardines and mackerel, consuming fortified dairy products, taking cod-liver oil and vitamin supplements, and in warmer weather briefly exposing skin to the sun’s vitamin-D producing ultraviolet light.

Aware of the cancer risks linked to too much time spent in the sun, she says as little as 10 to 15 minutes of daily exposure to the sun can produce sufficient amounts of vitamin D to sustain health. The hormone-like nutrient controls blood levels of calcium and phosphorus, essential chemicals in the body.

If vitamin supplements are used, Michos says there is no evidence that more than 2,000 international units per day do any good. Study results show that heart disease death rates flattened out in participants with the highest vitamin D levels (above 50 nanograms per milliliter of blood), signaling a possible loss of the vitamin’s protective effects at too-high doses.

The U.S. Institute of Medicine suggests that an adequate daily intake of vitamin D is between 200 and 400 international units (or blood levels nearing 30 nanograms per milliliter). Previous results from the same nationwide survey showed that 41 percent of men and 53 percent of women are technically deficient in the nutrient, with vitamin D levels below 28 nanograms per milliliter.

Michal Melamed, M.D., M.H.S., study co-lead investigator who started the research as a clinical fellow at Johns Hopkins, says no one knows yet why or how vitamin D’s hormone-like properties may protect the heart, but she adds that there are plenty of leads in the better known links the vitamin has to problems with muscle overgrowth and high blood pressure, in addition to its control of inflammation, which scientists are showing plays a stronger role in all kinds of heart disease. But more research is needed to determine the nutrient’s precise biological action.

Researchers say their next steps are to test various high doses of vitamin D to find out if the nutritional supplementation results in fewer deaths and lower incidence of heart disease, including heart attack or moments of prolonged and severe chest pain.

The team also plans to investigate what biological triggers, such as obesity or hypertension, might offset or worsen the action of vitamin D on heart muscle, or whether vitamin D sets off some other reaction in the heart.

Melamed says that because vitamin D levels are known to fluctuate in direct proportion with daily physical activity, the growing epidemic of obesity and indoor sedentary lifestyles lend more urgency to act on the vitamin D factor.

Funding for this study was provided by the National Institutes of Health, the P.J. Schafer Cardiovascular Research Fund and the Paul Beeson Physician Faculty Scholars in Aging Program. Michos has received previous consulting fees from vitamin D therapeutics manufacturer Abbott Pharmaceuticals. The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

Besides Michos and Melamed, other Hopkins researchers involved in this study, conducted solely at Hopkins, were Wendy Post, M.D.; and Brad Astor, Ph.D. Melamed is now an assistant professor at the Albert Einstein College of Medicine of Yeshiva University in New York City.

-----
Fayette Front Page
www.fayettefrontpage.com

Tuesday, July 29, 2008

Transplantation of Kidneys from Black Cardiac-Death Donors Provide Black Recipients with the Best Long-Term Survival

Contrary to prevailing assumptions, Johns Hopkins researchers have shown that kidneys recovered from black donors who died from cardiac death offer the best survival rate for black recipients of a deceased-donor kidney.

This discovery, released online this week and appearing in the October 2008 issue of the Journal of the American Society of Nephrology, challenges the long-held belief that kidneys from white brain-death donors offers the best deceased-donor transplant survival rate for either black or white recipients.

“Our findings indicate that increased use of kidneys from cardiac-death donors could help reduce the organ shortage and improve outcomes for black kidney transplant recipients,” says lead author Jayme Locke, M.D., M.P.H., of the Department of Surgery at Johns Hopkins.

Locke and a team of Johns Hopkins researchers examined the outcomes of more than 25,000 black adults who received a deceased-donor kidney transplant between 1993 and 2006.

Results showed that black recipients who received a kidney from a black cardiac-death donor had a 70 percent reduction in the risk of kidney loss and a 59 percent reduction in risk for death when compared to black recipients who received a kidney from a white brain-death donor.

“Our data is consistent with the previous observation that black recipients seem to do better with kidneys from white brain-death donors than they do with kidneys from black brain-death donors or white cardiac-death donors, however, the fact that black recipients have the best outcomes with kidneys from black cardiac-death donors is significant,” says co-lead author Daniel Warren, Ph.D., of the Department of Surgery at Johns Hopkins.

He says that the exact mechanisms responsible for racial differences in outcomes after kidney transplantation are not known, however, the results suggest that the genetic background of the donor and recipient likely have a significant impact on long-term outcomes.

“We believe that an improved understanding of the molecular consequences of cardiac and brain death is critical to improving outcomes for all kidney transplant recipients and warrants further investigation,” he added.

There are currently more than 70,000 Americans waiting for kidney transplants. Only about 600 deceased-donor kidneys donated after cardiac death are currently used for transplantation versus 7,000 donated after brain death.

This discrepancy is due in part to the belief that kidneys that are exposed to cardiac death generally suffer more damage than kidneys that are exposed to brain death.

“Our results show this is not always true, and that is significant news for all patients waiting for a kidney,” says Locke.

Other researchers who worked on this study from Johns Hopkins include Robert Montgomery, M.D., Ph.D.; Andrew Cameron, M.D.; Joseph Melancon, M.D.; Dorry Segev, M.D.; Andrew Singer, M.D., Ph.D.; Christopher Simpkins, M.D., M.P.H.; Andrea Zachary, Ph.D.; Francesca Dominici, Ph.D.; Mary Leffell, Ph.D.; and Deborah McRann, B.S.N.

Monday, July 28, 2008

Chemotherapy and Radiation After Surgery Prolongs Life for Pancreatic Cancer Patients

Pancreatic cancer patients treated with a combination of chemotherapy and radiation after surgery survive approximately six months longer than those receiving surgery alone, Johns Hopkins Kimmel Cancer Center scientists report.

Previous clinical trials conducted in the 1980s and 90s in the United States established the benefit of postoperative chemotherapy and radiation. However, experts still disagree on whether to administer the treatments because results from European studies suggest the opposite effect — a decrease in survival.

“Some physicians might avoid chemotherapy and radiation if a benefit in survival is uncertain. However, without proof, I believe it is a disservice to these patients if we eliminate chemotherapy and radiation,” says radiation oncologist Joseph Herman, M.D., who led the study.

Herman and his team sought to put the issue to rest by reviewing records of 616 Johns Hopkins patients whose pancreatic cancers were surgically removed between Aug. 30, 1993, and Feb. 28, 2005. The researchers compared the survival of 345 of the patients who had only surgery with 271 who were then treated with 5-fluorouracil (FU)-based chemotherapy agents and modern types of radiation.

Patients receiving the combined chemotherapy and radiation experienced an improved median survival when compared with patients who did not (21.2 vs. 14.4 months). Two-year survival also improved (43.9 percent vs. 31.9 percent), as did five-year survival (20.1 percent vs. 15.4 percent). Results were published in the July 20 issue of the Journal of Clinical Oncology.

“The take-home message of this study is that patients who received combined chemotherapy and radiation appeared to have better survival than patients who have surgery alone, suggesting that it is safe and beneficial if it’s done carefully and properly,” says Herman, assistant professor in the Department of Radiation Oncology and Molecular Radiation Sciences.

He cautions that this is a retrospective study and that selection bias was possible as they may have selected out those patients who are healthy enough to receive the chemotherapy and radiation. “Regardless, it is still encouraging to say that many of these patients had very aggressive cancer and a lot of them are still alive several years after they received this combination therapy,” says Herman.

Because data to assess treatment toxicity were unavailable, Herman and his study team focused on survival instead. He says the majority of patients were able to complete the therapy, suggesting that they tolerated it well.

The study also identified risk factors to determine those patients most likely to benefit from combined chemotherapy and radiation. Patients who clearly benefited included those with lymph-node-positive disease and those with tumors larger than 3 centimeters (about 1.2 inches). Patients with aggressive tumors also benefited, as did those with margin-positive disease, where the surgeon was unable to remove most of the tumor.

Groups were similar with respect to tumor size, nodal status and margin status, but those receiving combined chemotherapy and radiation were younger (median 64 vs. 70 years) and less likely to present with another serious disease.

“The survival benefit is still seen regardless of high-risk tumor characteristics and after controlling for age, other concurrent diseases and surgical complications,” Herman says.

Patients in this study received about five and a half weeks of combined chemotherapy and radiation, which is referred to as concurrent therapy. The therapy begins about four to eight weeks after surgery.

Most patients also received continuous-infusion 5-FU chemotherapy. This is a form of chemotherapy that enhances the ability of radiation to damage DNA, the building block of the rapidly dividing cancer cells. Patients take four weeks off at the conclusion of their initial therapy, and then may receive maintenance chemotherapy, as prescribed, in the weeks and months ahead.

Pancreatic cancer strikes about five out of 100,000 people each year in the United States. Because pancreatic cancer often has no symptoms in its early stages, cancerous tumors often go unnoticed until the cancer advances and individuals become ill. Prognosis is poor for long-term survival, with only about 5 percent of pancreatic cancer patients surviving five years after their diagnosis.

The most aggressive and effective form of treatment for pancreatic cancer is a complicated surgery commonly known as the Whipple procedure (used in this study), in which the gallbladder, common bile duct, part of the duodenum, and the head of the pancreas are generally removed. Johns Hopkins Hospital has performed more than 3,000 Whipple surgeries over the past 25 years.

The study was funded by the Johns Hopkins Department of Radiation Oncology and Molecular Radiation Sciences.

Michael Swartz, Charles Hsu, Jordan Winter, Timothy Pawlik, Elizabeth Sugar, Ray Robinson, Daniel Laheru, Elizabeth Jaffee, Ralph Hruban, Kurtis Campbell, Christopher Wolfgang, Fariba Asrari, Ross Donehower, Manuel Hidalgo, Luis Diaz, Charles Yeo, John Cameron, Richard Schulick and Ross Abrams, also from Johns Hopkins, assisted with this study.

Friday, July 18, 2008

Smothered Genes Combine with Mutations to Yield Poor Outcome

Johns Hopkins Kimmel Cancer Center researchers have identified a set of genes in breast and colon cancers with a deadly combination of traditional mutations and “smothered” gene activity that may result in poor outcomes for patients.

The Hopkins team showed that this smothering process, called epigenetic inactivation, contributes to the aggressiveness of breast and colon cancer by disrupting biochemical pathways that normally suppress the runaway growth of cells that is the hallmark of cancer. While mutations alter pathways by rewriting the gene’s DNA code, epigenetic marks affect genes without changing the code itself.

“Until studies like ours, it was easy to think that if we didn’t find gene mutations in certain biochemical pathways linked to breast or colon cancer, then those pathways were normal in such patients,” says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and deputy director of the Kimmel Cancer Center. “Now we know that, in some patients, the pathways involved with newly discovered mutated genes are often more frequently disrupted by epigenetic mechanisms rather than genetic ones.”

“That’s a powerful insight that could help us diagnose patients quicker, predict the course of their cancer more accurately and in the future treat the disease more effectively,” adds Baylin. A report on this work appeared May 27 in PLoS Medicine.

The team made their discovery using microarray technology – special silicon chips carrying pieces of genetic material that allow thousands of genes to be analyzed at one time. For this study, microarrays were tailored to locate cancer-related genes inactivated by an epigenetic process called DNA methylation. This methylation involves the binding of molecules called methyl groups to elements of DNA called cytosines that are located in a gene’s “on-off switch.” Excess methylation smothers the gene with too many methyl groups and interferes with the gene’s normal protein production, setting the stage for a lethal cancer.

Some 189 mutated genes in breast and colon cancers, previously identified by a Kimmel Cancer Center research team, were screened for methylation by Baylin’s group. They found 36 genes that were infrequently mutated in cancer, but were “hyper”methylated, often in both breast and colon cancers. After reviewing samples from 30 breast and 20 colorectal cancer patients as well as information from public microarray databases, the researchers found 18 of these genes that were strongly linked to poor outcome of patients with tumors carrying these changes.

For most of the genes, the researchers were able to reverse their epigenetic change and reactivate them in test tubes by stripping off excess methyl groups. This suggests that new treatments designed to reverse hypermethylation could be a simpler and more practical approach to treating cancer than strategies that attempt to replace, deactivate or compensate for mutated genes, according to Baylin.

Baylin also believes that the methlylated genes identified in this study could be inactivated in a broader range of cancers as well. That means the current findings could be extended to other cancers, improving the ability of physicians to predict the course of additional types of tumors, he says.

“We’ve learned from this study that we must include both genetic and epigenetic changes when we do future microarray analyses to increase our understanding of the genetic basis of cancer,” Baylin says. “Such information will provide new details about why cancers start and help us identify which cancers will be particularly aggressive in our patients.”

Participants in the study included Timothy Chan, Sabine Glockner, Joo Mi Yi, Wei Chen, Leslie Cope, James Herman, Victor Velculescu, Kornel Schuebel, and Nita Ahuja of Johns Hopkins, and Leander Van Neste of Ghent University, Belgium.

This work was supported by the National Institute of Environmental Health Sciences and the National Cancer Institute.